Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe | GenomeWeb

By Doug Macron

Drug makers Novartis and Alcon have joined Alnylam Pharmaceuticals in opposing a European patent held by Silence Therapeutics covering a key RNAi molecule-design technology, according to documents on file with the European Patent Office.

The companies are asking the EPO to revoke the patent because, they say, the intellectual property lacks novelty in light of prior art, among other things.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.